AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...

the Humira molecule was losing patients to other novel mechanisms and Skyrizi and Rinvoq were picking up some of that. It's not what's driving the momentum for Skyrizi and Rinvoq, but it certainly ...

Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, California 93106, United States Biomolecular Science and Engineering Program, University of California ...

"These findings illuminate a critical mechanism that connects local synaptic activity to the broader gene expression changes necessary for learning and memory," said Mark Dell'Acqua, professor of ...